No Data
ASCLETIS-B (01672.HK) spent HKD 0.634 million to repurchase 0.26 million shares on December 19.
Gelonghui reported on December 19 that ASCLETIS-B (01672.HK) announced that on December 19, 2024, it spent 0.634 million Hong Kong dollars to repurchase 0.26 million shares.
Hong Kong stock announcement to uncover opportunities | SHOUCHENG intends to sell approximately 0.607 billion shares of SHOUGANG RES for about 1.4566 billion Hong Kong dollars.
IDREAMSKY (01119) has reached a collaboration with stc play in the fields of technology and gaming. ASCLETIS-B (01672): The weight loss candidate drug ASC47, which treats obesity, has shown better weight loss effects than single-agent semaglutide in preclinical models when used in combination.
ASCLETIS-B (01672.HK): The candidate drug ASC47 for treating obesity, which does not reduce muscle, has shown superior weight loss effects compared to semaglutide monotherapy in preclinical models when used in combination.
On December 18, Gelonghui reported that ASCLETIS-B (01672.HK) announced that the Board of Directors stated that the novel candidate drug ASC47 for treating obesity, which does not reduce muscle mass, showed encouraging efficacy when combined with semaglutide in studies using a diet-induced obesity (DIO) mouse model. ASC47 is a thyroid hormone receptor β (THRβ) selective small molecule agonist independently developed by ASCLETIS, designed for targeting fat with once monthly subcutaneous injections. ASC47 has unique differentiated characteristics, allowing it to target fat and produce dose-dependent high drug concentrations in fat tissues. In Australia.
Express News | Ascletis Pharma Inc - Asc47 in Combination With Semaglutide Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.
Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to
Investors Bid Ascletis Pharma (HKG:1672) up HK$455m Despite Increasing Losses YoY, Taking One-year Return to 50%
